Cooperative effect of gag proteins p12 and capsid during early events of murine leukemia virus replication.
The Gag polyprotein of murine leukemia virus (MLV) is processed into matrix (MA), p12, capsid (CA), and nucleocapsid (NC) proteins. p12 affects early events of virus replication and contains a PPPY motif important for virus release. To probe the functions of p12 in the early steps of MLV replication, we tested whether p12 can be replaced by spleen necrosis virus (SNV) p18, human immunodeficiency virus type 1 p6, or Rous sarcoma virus p2b. Analyses revealed that all chimeras generated virions at levels similar to that of MLV gag-pol; however, none of them could support MLV vector replication, and all of them exhibited severely reduced DNA synthesis upon virus infection. Because a previously reported SNV gag-MLV pol chimera, but not the MLV hybrid with SNV p18, can support replication of an MLV vector, we hypothesized that other Gag proteins act cooperatively with p12 during the early phase of virus replication. To test this hypothesis, we generated three more MLV-based chimeras containing SNV CA, p18-CA, or p18-CA-NC. We found that the MLV chimera containing SNV p18-CA or p18-CA-NC could support MLV vector replication, but the chimera containing SNV CA could not. Furthermore, viruses derived from the MLV chimera with SNV CA could synthesize viral DNA upon infection but were blocked at a post-reverse-transcription step and generated very little two long terminal repeat circle DNA, thereby producing a phenotype similar to that of the provirus formation-defective p12 mutants. Taken together, our data indicate that when p12/p18 or CA was from different viruses, despite abundant virus production and proper Gag processing, the resulting viruses were not infectious. However, when p12/p18 and CA were from the same virus, even though they were from SNV and not MLV, the resulting viruses were infectious. Therefore, these results suggest a cooperative effect of p12 and CA during the early events of MLV replication.
Lee
Sook-Kyung
SK
HIV Drug Resistance Program, National Cancer Institute at Frederick, Frederick, MD 21702, USA.
Nagashima
Kunio
K
Hu
Wei-Shau
WS
D036022:Capsid Proteins / Q000235:genetics / Q000502:physiology*; D004270:DNA, Circular / Q000096:biosynthesis; D004279:DNA, Viral / Q000096:biosynthesis; D015683:Gene Products, gag / Q000235:genetics / Q000502:physiology*; D005814:Genes, Viral; D009052:Leukemia Virus, Murine / Q000235:genetics / Q000502:physiology* / Q000648:ultrastructure; D008854:Microscopy, Electron; D009154:Mutation; D012367:RNA, Viral / Q000378:metabolism; D011995:Recombination, Genetic; D048348:Reverse Transcription; D014764:Viral Proteins / Q000235:genetics / Q000502:physiology; D014771:Virion / Q000502:physiology / Q000648:ultrastructure; D019065:Virus Assembly / Q000235:genetics; D014779:Virus Replication; D054301:gag Gene Products, Human Immunodeficiency Virus
D036022:Capsid Proteins; D004270:DNA, Circular; D004279:DNA, Viral; C468293:Gag protein p12, moloney murine leukemia virus; D015683:Gene Products, gag; D012367:RNA, Viral; D014764:Viral Proteins; D054301:gag Gene Products, Human Immunodeficiency Virus; C083002:p6 gag protein, Human immunodeficiency virus 1